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e abnormal deposition of proteins in and around neurons is a common pathological feature of many neurodegenerative
diseases. Among these pathological proteins, the microtubule-associated protein tau forms intraneuronal �laments in a spectrum
of neurological disorders. e discovery that dominant mutations in the MAPT gene encoding tau are associated with familial
frontotemporal dementia strongly supports abnormal tau protein as directly involved in disease pathogenesis. is and other
evidence suggest that tau is a worthwhile target for the prevention or treatment of tau-associated neurodegenerative diseases,
collectively called tauopathies. However, it is critical to understand the normal biological roles of tau, the speci�c molecular
events that induce tau to become neurotoxic, the biochemical nature of pathogenic tau, the means by which pathogenic tau exerts
neurotoxicity, and how tau pathology propagates. Based on known diﬀerences between normal and abnormal tau, a number of
approaches have been taken toward the discovery of potential therapeutics. Key questions still remain open, such as the nature of
the connection between the amyloid-𝛽𝛽 protein of Alzheimer’s disease and tau pathology. Answers to these questions should help
better understand the nature of tauopathies and may also reveal new therapeutic targets and strategies.
1. Introduction
1.1. Protein Aggregation in Neurodegenerative Diseases. Cells
and organisms devote considerable time and energy toward
the proper folding of proteins upon biosynthesis from ribo-
somes and prevention of inappropriate protein aggregation
[1, 2]. Nevertheless, misfoldings and aggregations do occur,
with some proteins being more susceptible than others.
Such events would quickly cause problems without means of
identifying misfolded and aggregated proteins and clearing
them out. Despite the multiple means of chaperoning and
correctly folding proteins and clearing out misfolded and
aggregated ones, a variety of protein folding disorders can
develop in humans as well as other organisms. One example
is sickle cell anemia, in which a single missense mutation in
the𝛽𝛽-globin chain of haemoglobin leads to noncovalent poly-
merization and dysfunctional red blood cells [3]. Another
is transthyretin amyloidosis, in which mutant transthyretin,
a protein that normally transports thyroid hormone and
vitamin A, aggregates in the form of amyloid deposits in the
heart, kidney, nerves and intestines [4].
Neurons can be particularly sensitive to the eﬀects ofmis-
folded, aggregated proteins, because these cells are oen in
place for life aer they become fully diﬀerentiated and post-
mitotic. Furthermore, their narrow axonal projections can
be quite long, providing many opportunities to clog up the
system and interfere with essential transport of biomolecules
and organelles. Once axons become blocked by aggregated
proteins, neurons can then degenerate from axon to cell body.
us, the unique biology of neurons is likely the reason why
abnormal protein deposition is a common feature in a variety
of neurodegenerative diseases [5]. ese include Alzheimer’s
disease (AD), characterized by the extraneuronal deposition
of the amyloid 𝛽𝛽-protein (A𝛽𝛽) in the form of plaques and
the intraneuronal deposition of the microtubule-associated
protein tau in the form of �laments; Parkinson’s disease
(PD), with neuronal deposits of 𝛼𝛼-synuclein; Huntington’s
disease (HD), with cytoplasmic and nuclear deposition of
the huntingtin protein and fragments thereof; amyolateral
sclerosis (ALS), characterized by TAR DNA-binding protein
43 (TDP-43) deposition in ubiquitin-positive inclusions; the
prion diseases, such as Creutzfeldt-Jakob disease (CJD) in
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humans, mad cow disease in bovines, and scrapie in sheep,
which are characterized by the aggregation of extraneuronal
plaques of the prion protein.
ere has been considerable debate about the pathogenic
nature of the protein deposits per se. Indeed, dissociation
between protein deposition and neurodegeneration appears
to be the casewithHD [6] and prion diseases [7] andmaywell
be true of other neurodegenerative diseases [5]. Nevertheless,
it is now clear that abnormal forms of these proteins, if
not plaques and other microscopically observable deposits,
are directly involved in initiating neurodegeneration. is
is because missense mutations in the genes encoding each
of these proteins (or their precursors) are associated with
dominant, inherited forms of their respective diseases. In all
of these genetic forms of the disease, mutation of the protein
leads to the characteristic pathology, neurodegeneration,
and, ultimately, disease onset and progression. Why disease
onset takes decades is unclear but may be due to a reduced
ability to clear out misfolded and aggregated proteins with
age. is might explain why sporadic Alzheimer’s disease
oen does not present until aer age 70, and its prevalence
is as high as 50% among those over age 85.
1.2. Tau as a Common Pathological Marker in Many Neurode-
generative Diseases. Tau deposition in the form of intraneu-
ronal �laments is found not only in AD, but in a variety of
other neurodegenerative diseases collectively referred to as
tauopathies [8, 9]. ese include a spectrum of diseases now
placed under the umbrella name of frontotemporal demen-
tias (FTD) (e.g., Pick’s disease, corticobasal degeneration,
progressive supranuclear palsy, frontotemporal lobar demen-
tia with parkinsonism linked to chromosome 17 (FTDP-17),
and dementia pugilistica). FTD is the second most common
form of presenile dementia aer AD. Tau pathology is also
oen seen in some forms of PD, ALS, and prion diseases,
although it is not characteristically the most common feature
of these other neurodegenerative disorders.
At the microscopic level, tau deposition is readily
observed post mortem through silver staining of brain slices
[10]. Filaments are found in neuronal extensions, leading
to abnormal processes referred to as neuro�brillary tangles
(NFTs) by Alois Alzheimer, who �rst described this type of
pathology in an AD brain in 1906. Although tau is normally
found primarily in axons, with smaller levels in dendrites,
it can form �laments in dendrites and in the neuronal cell
body, suggesting missorting. Although both amyloid plaques
(of A𝛽𝛽) and neuro�brillary tangles (of tau) are both common
pathological features in AD, the latter correlate more closely
with neurodegeneration. is observation, as well as others
described later, suggests that aberrant tau might mediate
A𝛽𝛽 pathogenicity and be more proximal to neurotoxicity in
the pathogenic pathway leading to AD. In genetic forms of
FTD, mutations in tau clearly implicate abnormal tau as the
initiator of neurodegeneration and disease [11].
e particular type of neurodegeneration that manifests
itself is determined by the neurons and networks of neurons
in which misfolded tau accumulates and aggregates. In AD,
tau pathology apparently �rst occurs in the entorhinal cortex,
and then spreading to the hippocampus and cerebral cortex
[12–16]. As these brain regions play critical roles in learning
and memory, the primary problem in AD is cognitive
de�cits. In FTD, tau generally deposits in the frontal and
temporal lobes [8], regions of the brain that are important for
executive functions and behavior.us, the �rst signs of FTD
are typically irrational decisions and socially inappropriate
behavior. However, tau pathology can also be found in other
brain areas (e.g., basal ganglia and subthalamus) depending
on the speci�c type of FTD (e.g., progressive supranuclear
palsy).
Why particular neurons are susceptible to the buildup of
misfolded tau and tau aggregation is unknown. For wild-type
tau, stochastic events may trigger misfolding and aggregation
in a given neuron or set of neurons. However, certain
mutations of tau are associatedwith speci�c forms of FTD [8],
suggesting that speci�c neurons and neuronal networks are
especially susceptible to those particular mutations. On the
other hand, the same mutation (P301L) can apparently lead
to corticobasal degeneration or FTDP-17 in the same family,
suggesting that other genetic, epigenetic, or environmental
factors may in�uence which neurons are aﬀected. Regardless
ofwhy speci�c neurons are aﬀected, it is critical to understand
the normal role of tau and how it becomes pathogenic in
order to consider strategies for prevention and treatment.
2. Tau Biology
2.1.e TauGene andHaplotypes. MAPT, the gene encoding
the tau protein, located on chromosome 17q21.3, spans
∼150 kb and consists of 16 exons, 11 of which are expressed in
the central nervous system [17]. Two main haplotypes exist,
H1 and H2, resulting from an ancient inversion of a ∼900 kb
region that includes the entire MAPT gene. Although the
amino acid sequence between H1 and H2 tau is unchanged,
these haplotypes do diﬀer in a set of de�ned single nucleotide
polymorphisms (SNPs) and a 238 bp deletion in intron 9 in
H2. Interestingly, the H1 haplotype is much more diverse
than is H2, which is relatively invariant and found almost
entirely in those of European ancestry. While the H1 and
H2 inversion is estimated to have occurred ∼3 million
years ago, the H2 haplotype was apparently reintroduced
in the European population some 10,000–30,000 years ago.
Since Homo sapiens and Homo neanderthalensis coexisted in
Europe during that time, it was suggested that Neanderthals
may have reintroduced H2 into the Homo sapien genome
[18]. Recent determination of the Neanderthal genome,
however, does not support this contention [19].
Although H1 has been reported to be overrepresented
in Caucasian cases of progressive supranuclear palsy [20]
and sporadic PD [21], the association with MAPT per se is
unclear. Considering the diversity of the H1 haplotype, more
re�ned analyses support a particular subhaplotype, H1c,
being highly associated with PSP and CBD, with H2 being
strongly negatively associated [22]. e H1c subhaplotype
has also been reported to be associated with sporadic AD
[23], although this has been controversial. Since the H1
and H2 haplotypes do not diﬀer with respect to tau protein
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sequence, any pathogenic eﬀects associated with a particular
haplotype or subhaplotype may instead be due to diﬀerences
in transcription, splicing or other posttranscriptional modi-
�cations, transcript stability or localization, or rates of trans-
lation. It is already clear that silent or intronic mutations that
shi tau pre-mRNA alternative splicing can cause familial
FTD (see below), and recent evidence suggests that the H1c
subhaplotype is associatedwith a similar alteration in splicing
[24, 25].
2.2. Protein Expression, Sequence, and Splice Isoforms. Tau
protein is expressed in a variety of mammalian tissues, being
found at relatively high levels in the heart, skeletal muscle,
lung, kidney, and testis and at low levels in the adrenal gland,
stomach, and liver [26]. However, it is most highly enriched
in neurons in the central nervous system. is makes sense,
as tau is a microtubule-associated protein [27, 28], and
microtubules are especially important to neuronal structure
and function.e tau protein is primarily foundwithin axons
[29], although it is also found at low levels normally in
dendrites [30]. Abnormal accumulation of tau in somatoden-
dritic compartments is associated with Alzheimer’s and other
tauopathies [31].
e tau protein contains several imperfectly repeated
18-residue microtubule-binding domains in the C-terminal
region [32–34] (Figure 1).ese are linked through a proline-
rich region to an acidic N-terminal region (also called the
projection domain) [35]. e tau pre-mRNA undergoes
alternative splicing at exons 2, 3, and 10 to give six diﬀerent
possible isoforms [36]. Exons 2 and 3, encoding 29-residue
stretches near the N-terminus, undergo coupled splicing,
with exon 2 inclusion being dependent on exon 3 inclusion.
Variations in exon 2/3 splicing are referred to at 0N (neither
included), 1N (exon 3 included), or 2N (both exons 2 and 3
included). Exon 10 encodes 31 amino acids and the second
of four possible microtubule binding domains. Inclusion of
exon 10 generates 4-repeat or 4R tau, while exclusion forms
3-repeat or 3R tau [36–38]. A small degree of alternative
splicing can also occur in exon 6, resulting in other very
minor tau isoforms [39].
e expression of the diﬀerent tau isoforms in the brain is
under developmental control, suggesting that the regulation
of tau isoforms is important during formation of the brain.
Human fetal tau is almost exclusively 0N/3R tau, while adults
express all six isoforms [38, 40]. Disruption of the normal
4R-to-3R ratio is associated with neurodegeneration (see
the following). Consistent with an important role of tau in
brain development, microdeletions in MAPT are associated
with mental retardation [41, 42], and knockdown of tau can
result in reduced neuronal connectivity in the brain [43].
Despite these observations, complete knockout of tau in
mice yields viable and fertile animals with grossly normal
brain anatomy and no evidence of neurodegeneration [44–
48], although this may be due to functional redundancy
with other microtubule-associated proteins (MAPs). Of four
independent tau knockout lines that have been established
so far, only one has been reported to have motor de�cits
and hyperactivity, with debatable learning impairments [46].
F 1: Domains and splice isoforms of tau. Exons 2, 3 and 10
are alternatively spliced. Inclusion/exclusion of exons 2 and 3 are
denoted as 0N, 1N, or 2N. Inclusion/exclusion of exon 10, encoding
the second of four possible repeated microtubule binding domains,
are denoted as 3R or 4R.
No de�cits of any kind have been reported in hemizygous
knockout mice.
2.3. Phosphorylation. e tau protein can undergo a variety
of phosphorylation events at its many serine, threonine, and
tyrosine residues, although most occur at Ser/r-Pro sites
[49]. Some 30 or more possible phosphorylation sites are
found in every tau isoform. ese phosphorylations can
control the normal biological functions of tau, such as its role
in microtubule stability, as well as its pathological functions,
such as its ability to self-assemble into neuronal �laments
found in neurodegenerative diseases. e functions, if any,
either physiological and pathological, of many of these phos-
phorylations are unknown, and in some cases it is unclear if
they even occur in vivo. Moreover, these phosphorylations
can be mediated by numerous candidate kinases in vitro,
but the ability of many of them to carry out the speci�c
phosphorylations of tau in cells and in vivo at physiological
levels and locations is likewise unclear. A diagram showing
sites on tau that have been reported to be phosphorylated is
depicted in Figure 2.
Some of these phosphorylations, however, do appear to
be particularly relevant. Among these are Ser202, r205,
Ser396, Ser404, as well as repeated KXGS motifs located
within each microtubule binding domain. e microtubule-
aﬃnity-regulating kinase (MARK) selectively phosphorylates
the KXGS motifs, particularly the one including Ser262 [50,
51]. Phosphorylations at these sites reduce the aﬃnity of
tau for microtubules and may thereby regulate microtubule
formation and function [52, 53]. e glycogen synthase
kinase 3𝛽𝛽 (GSK3𝛽𝛽) and cyclin-dependent kinase 5 (cdk5)
are also associated with many of tau phosphorylations, both
in vitro and in vivo, although the ability of cdk5 to do so
directly in vivo is unclear [54, 55]. Cdk5 is activated by the
noncyclin regulatory proteins p39 and p35 in postmitotic
cells; however, proteolysis of p39 and p35 by calpain to
p29 and p25, respectively, results in prolonged half-life of
these regulatory proteins and, therefore, prolonged cdk5











































































































































































































F 2: Sites of phosphorylation in tau and the kinases implicated.
is also especially implicated in tau phosphorylations [56, 57].
Although tau is hyperphosphorylated in AD, it is unclear
which particular sites are relevant, or even whether hyper-
phophorylation occurs before or aer �lament formation.
Tau can also undergo dephosphorylation by phosphatases
such as PP1 and PP2A. e balance between kinase activity
and phosphatase activity is critical to the phosphorylation
state of tau and therefore to tau function and dysfunction.
2.4. Role of Tau in Microtubule Formation, Stability, and
Dynamics. e most studied cellular role of tau is in its
interaction with and eﬀects on microtubules. While micro-
tubules are most noted in cell biology for the formation of the
mitotic spindle during cell division, these polymers of tubulin
are essential to postmitotic cells as well. Microtubules are
particularly important for neuronal integrity and function,
providing structure to the axonal processes that extend from
the neuronal cell body and a path for the transport of
materials to and from the oen relatively distant synapses.
Tau is involved in the assembly and stability of microtubules
[27, 28], roles that have been extensively studied; however, in
vivo, tau may be more involved in microtubule dynamics, in
the assembly/disassembly process critical to axonal transport.
In addition, the gradient of tau along the axon, with levels
highest at the synapse [58], likewise suggests a role in axonal
transport, and tau can block the binding of motor proteins
that move materials along microtubules [59, 60]. us, the
high levels of microtubule-bound tau near synapses may
favor the release of motor proteins and their cargo where
needed.
As mentioned earlier, despite these seemingly critical
functions of tau, tau knockout mice are viable, fertile,
and relatively normal, with no signs of neurodegeneration.
Furthermore, knockdown of tau with siRNA does not kill
primary neurons in culture or prevent axon formation [61].
us, tau is not essential to neurons or to microtubules,
likely due to compensation by and/or redundant functions
of other proteins. Indeed, the microtubule-associated protein
1B (MAP1B), also found primarily in axons, apparently
plays such roles. MAP1B is likewise involved in microtubule
stability, and knockout of MAP1B results in abnormal brain
development and early death [62]. Knockout of both tau and
MAP1B worsens this phenotype [62]. However, to determine
if MAP1B or other factors compensate for the loss of tau
during development, conditional tau knockout mice should
be generated in order to abrogate tau in the adult mouse
brain. Addressing this issue is critical for determining how
misfolded or aggregated tau might cause neurodegeneration
(discussed in more detail later).
2.5. Other Tau Functions. Tau has been reported to interact
with a number of other proteins besides tubulin/microtubules
[63], although the biological relevance of many of these
interactions is not clear. However, in recent years evidence
has been mounting that the interaction between tau and
the protein kinase Fyn may be important for modulating
neuronal cell signaling through Fyn [30]. As mentioned
earlier, tau is found normally at low levels in dendrites,
colocalizing with Fyn and the postsynaptic density protein 95
(PSD95).ese three proteins can be coimmunoprecipitated,
suggesting that tau may be serving as a scaﬀolding protein
along with PSD95 to localize Fyn at synapses, enabling Fyn
activation through NMDA receptors. Indeed, tau is required
for phosphorylation of NMDA receptor subunit NR2B in
dendrites. e tau-Fyn interaction may also play a role in
process extension in oligodendrites [64].
3. Tau in Neurodegenerative Diseases
3.1. Alzheimer’s Disease
3.1.1. Amyloid and Tau. e AD brain is characterized by
extraneuronal deposits of A𝛽𝛽 and intraneuronal �laments
of tau [10]. A𝛽𝛽 is produced through proteolytic processing
of the type I integral membrane protein amyloid 𝛽𝛽-protein
precursor (APP) [65] (Figure 3). e membrane-tethered
𝛽𝛽-secretase sheds the APP ectodomain [66], followed by









Neuronal cell death Clinical AD
F 3: e amyloid hypothesis of Alzheimer’s disease and the
role of tau. Evidence supports the formation and aggregation of
the amyloid 𝛽𝛽-protein as the initiator of the disease process, with
tau playing a subsequent role. Possible A𝛽𝛽-induced pathological
changes in tau include hyperphosphorylation or aggregation.
domain by the 𝛾𝛾-secretase complex [67]. Dominant missense
mutations that cause early-onset, familial AD are found in
the APP gene, in and around the small (4 kDa) A𝛽𝛽 region
of the much larger APP, and these mutations aﬀect the
level, type, or aggregation properties of A𝛽𝛽 produced [68].
Dominant missense mutations are also found in Presenilin,
the protein of which is the catalytic component of 𝛾𝛾-secretase,
and these mutations also change the type of A𝛽𝛽, increasing
the proportion of longer, more aggregation-prone forms of
the protein [68]. No mutations in MAPT have been found
associated with AD. Rather, such mutations are associated
with FTD (discussed later). us, human genetics supports
A𝛽𝛽 as the initiator of AD pathogenesis [68]. However, tau
is a common feature of a spectrum of neurodegenerative
diseases, and A𝛽𝛽 may be one of many possible ways of
triggering tau pathology [9].
Further evidence that tau is downstreamofA𝛽𝛽 but critical
to AD pathogenesis comes frommouse studies. Mice that are
doubly transgenic for human APP and presenilin-1 carrying
familial AD mutations display amyloid plaques pathology
and learning and memory de�cits [69]. Crossing these mice
with tau knockout mice revealed that loss of tau did not
aﬀect APP expression, A𝛽𝛽 production, or plaque formation
[47]. However, the cognitive de�cits were rescued in a gene-
dosage-dependent manner, with loss of one tau allele provid-
ing partial rescue. In addition, a seizure phenotype observed
in the transgenic mice was likewise rescued. Surprisingly
though, in another report, crossing a tau knockout with a
human mutant APP mouse led to increased axonal degen-
eration [70]. Mice transgenic for human tau can show tau
pathology and cognitive and behavioral de�cits [9]. However,
crossing these mice with the APP/Presenilin-1 mice resulted
in triple transgenic mice with increased tau pathology,
along with amyloid pathology, and more severe learning
and memory de�cits [71]. Treatment of the triple transgenic
mice with anti-A𝛽𝛽monoclonal antibodies attenuated the tau
pathology as well as the cognitive de�cits [72]. Overall, these
�ndings suggest that tau is part of the pathogenic process
subsequent to A𝛽𝛽 and might be a worthwhile target for
therapeutic intervention.
Cellular studies also support the ability of A𝛽𝛽 to aﬀect
tau. Treatment of neuronal cultures with A𝛽𝛽 can lead to
hyperphosphorylation of tau [73, 74], although this has not
been observed in APP transgenic mice with endogenous
tau expression. Perhaps due to the increase in tau phospho-
rylation and reduced aﬃnity of tau for microtubules, A𝛽𝛽
treatment can also induce the inappropriate increase of tau
in dendritic spines, a phenomenon that correlates with a
degree of spine degeneration [74]. Most recently, dimeric
A𝛽𝛽 isolated from postmortem human AD brains has been
reported to cause tau hyperphosphorylation in cultured rat
hippocampal neurons, release of tau from microtubules, and
neurite degeneration [75]. Moreover, A𝛽𝛽 oligomers con-
taining a truncated, N-terminally pyroglutaminylated form
of A𝛽𝛽 implicated in AD pathogenesis were found to be
highly toxic to cultured neurons in a tau-dependent manner
[76]. However, despite the possibility that A𝛽𝛽 may aﬀect
tau phosphorylation, mislocalization, and neuronal health,
the ability of A𝛽𝛽 to cause assembly of endogenous tau into
oligomers or �laments has not been observed.
How A𝛽𝛽 might cause these changes in tau is not clear.
However, one possible connection is through the protein
tyrosine kinase Fyn, which, as mentioned earlier, can inter-
act with tau and PSD95 in dendrites and thereby trigger
phosphorylation of the NMDA receptor subunit NR2B. e
cellular prion protein (PrPc) has been recently reported
as a receptor for soluble A𝛽𝛽 oligomers [77], forms of A𝛽𝛽
more implicated in AD pathogenesis than amyloid plaques.
is interaction can lead to increased Fyn activity and
NR2B phosphorylation in neurites. Whether knockout or
knockdown of tau can alter this aﬀect of A𝛽𝛽 remains to be
tested, but as pointed out previously, tau is required for NR2B
phosphorylation by Fyn in dendrites. Further evidence for an
A𝛽𝛽-Fyn-tau pathogenic pathway in AD: Fyn overexpression
worsens the neuronal and cognitive phenotype of APP
transgenic mice [78, 79], and this eﬀect is attenuated by
knockout of tau [80].
3.1.2. Loss versus Gain of Function. e question of whether
aberrant tau is pathogenic due to a loss of function or a
gain of function has been debated considerably over the
years. On the one hand, hyperphosphorylation of tau and
tau aggregation may lead to less tau that is capable of
facilitating microtubule formation, stability, and dynamics.
Asmicrotubules are especially important for neuronal health,
particularly in axons, reduction of functional microtubules
would lead to disruption in the transport of molecules and
organelles to and from the synapse, thereby resulting in
synaptic dysfunction and degeneration. On the other hand,
hyperphosphorylated and/or aggregated forms of tau may
result in a toxic gain of function, in which the aberrant
species per se cause neuronal dysfunction and degeneration.
e aggregated forms, for instance, may block the axon to
prevent proper transfer of materials along microtubules. It
seems clear that pathogenesis is not strictly due to a loss of
function; as the tau knockout mice do not display neurode-
generation, tau can be knocked down in neuronal cultures
without causing cell death or preventing axon formation, and
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none of the FTD-causing MAPT mutations cause deletion
or truncation of the protein. ese facts, however, do not
preclude that a reduction of microtubule-associated tau, due
to tau hyperphosphorylation and/or aggregation, may be a
secondary contributor to neuronal dysfunction and death
along with the primary contributor, an aberrant gain of toxic
function.
3.1.3. e Spread of Tauopathy. Tau pathology in AD is
�rst observed in the entorhinal cortex [12]. is region
of the brain, located in the caudal end of the temporal
lobe, is connected to the hippocampus and the neocortex
and critical for memory formation and consolidation. From
the entorhinal cortex, tau pathology spreads, apparently
from neuron to neuron via synaptic connections, to the
hippocampus, and then to the neocortex [12]. Studies in cell
culture have shown that extracellular aggregates of tau can be
taken up by cells through endocytosis and cause aggregation
of intracellular tau that then spreads throughout the culture
[81–83]. Similar experiments have been performed in vivo, in
which brain extracts containing aggregated tau were injected
into the brains of mice transgenic for human tau, leading
to aggregation of tau expressed from the transgene and the
spreading of tau pathology into connected regions of the
brain [84].
Most recently, mice were engineered to express human
P301L tau speci�cally in the entorhinal cortex in response to
tetracycline treatment [15, 16]. is mutation causes familial
frontotemporal dementia with typical tau pathology. Induc-
tion ofmutant tau expression in the entorhinal cortex in adult
mice resulted in tau aggregation and neurodegeneration in
this speci�c region. From there, the pathology spread to the
hippocampus and neighboring regions, areas in which only
endogenousmouse tauwas expressed at normal physiological
levels. With the caveat that very low levels of the mutant
transgenic tau might have been expressed in areas other than
the entorhinal cortex, the results suggest that pathological
tau can induce similar aggregated states in normal tau in
neighboring or connected neurons. Such a process is remi-
niscent of the mechanism by which prion proteins propagate:
a pathological conformation that leads to aggregation can
induce normal forms of the protein to take on the same
pathological conformation [86]. While tau is not infectious
like pathological prion proteins, it can apparently propagate
a pathological conformation from neuron to neuron in a
similar manner.
How aberrant tau might spread from one neuron to
another though is unclear. One possibility is that misfolded
and aggregated tau is released upon neuronal cell death,
whereupon it is taken up by neighboring neurons via endocy-
tosis. Another is that tau is somehow secreted from neurons,
even though it is not the kind of protein that generally enters
the secretory pathway. A particularly intriguing alternative
is that tau is contained within exosomes [87], microvesicles
that are released from the cell when multivesicular bodies
fuse with the plasma membrane. Subsequent fusion with the
membrane of a neighboring neuron results in uptake. e
fact that tau is released, whether by dead neurons or live,
by secretion or in exosomes, is clear: tau is detectable in
human cerebral spinal �uid �CSF�, and an increase in CSF tau
correlates with AD. Indeed, CSF tau or phosphorylated tau is
a leading biomarker for prodromal AD [88].
3.1.4. Oligomers versus Aggregates. For both amyloid plaques
and tau �laments, a major question for many decades has
been whether these microscopic deposits are involved in
the pathogenesis of AD, are markers where neuronal cell
death anddestruction have already occurred, or are otherwise
tightly coupled to the actual pathogenic forms of the proteins.
e formation of insoluble aggregates of A𝛽𝛽 or tau could
even be a protective response, reducing the levels of the real
neurotoxic species and allowing the clearance of these pro-
teins through processes such as phagocytosis or autophagy.
For A𝛽𝛽, this may well be the case, as amyloid deposits per se
do not correlate well with neurodegeneration [89]. Tau �la-
ment formation and neuro�brillary tangles are more closely
correlated with neurodegeneration than amyloid plaques are.
For A𝛽𝛽, soluble oligomeric forms of the protein, rather than
insoluble deposits, have been especially implicated in AD
pathogenesis [90]. As for tau, soluble oligomers at the very
least appear to be on the pathway to NFTs [91–93] and may
well be pathogenic themselves.
Neuronal cell death and synaptic defects have been seen
independent of tau-containing NFTs in mice transgenic for
wild-type human tau [94, 95]. Loss of synapses in the
hippocampus, impaired synaptic function, and microglio-
sis also occurred before formation of NFTs in an FTD-
mutant human tau mouse model [96], observations that
have been reported in other tau animal models as well
[97, 98]. Intriguingly, a mouse line with inducible FTD-
mutant tau recovered in cognitive function and stabilized
in number of neurons upon lowering transgenic expression,
even thoughNFT formation continued [99]. Moreover, accu-
mulation of oligomeric tau correlated better than NFTs with
neurodegeneration and behavioral de�cits in two diﬀerent
tau transgenic mouse models [100, 101]. In human AD,
neuronal loss can apparently precede NFT formation [13],
and granular tau oligomers have been detected and isolated at
very early stages of the disease [91, 102]. Taken together, these
results suggest that tau oligomer accumulation, neuronal loss,
and behavioral de�cits occur before the formation of NFTs.
Nevertheless, it seems diﬃcult to envision that accumulation
of tau �laments in neuronal soma and processes can be
consistent with a healthy, functioning neuron. Indeed, extra-
neuronal tau �laments are found in the shape of neuronal
cell bodies, and hence their name “ghost tangles” [103].
NFTs are not likely harmless, although perhaps they are
less deleterious than soluble tau oligomers. However, few
studies have examined tau oligomers in AD patients. e
development of tau oligomer-speci�c antibodies [93] may
oﬀer an important new tool to elucidate the role of soluble
tau aggregates in AD pathogenesis.
3.1.5. Proteolysis. e proteolytic degradation of tau has
been implicated in the pathogenesis of AD. A number of
diﬀerent proteases have been found capable of cleaving tau,
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at least in vitro [104]. Among these proteases, caspases are
perhaps the most validated. Caspases are cysteine proteases
that cleavage substrates with aspartate residues in position
P1. ese proteases are produced as inactive zymogens, and
activation of certain caspases is a key step in programmed
cell death or apoptosis. Several caspases are capable of
proteolyzing tau at D421 (2N/4R isoform numbering), close
to the C-terminus, to generate a fragment ∼5 kDa smaller.
is truncation of tau has been validated both in vitro and in
vivo and is found in NFTs in the AD brain, although its role
and that of caspase-3 in pathogenesis are unclear [105–110].
Interestingly, treatment of cultured cells with A𝛽𝛽 leads
to tau cleaved at D421, and such truncated tau can facilitate
aggregation [105, 111].us, a pathway has been suggested in
which neurotoxic forms of A𝛽𝛽 can induce caspase cleavage of
tau to the D421-truncated form, providing seeds for the �la-
ment formation of full-length tau. However, such aggregation
of endogenous tau upon expression of truncated tau in cells
has not been observed, except when coexpressedwithGSK3𝛽𝛽
[112]. e meaning of this is unclear, as pseudophosphory-
lation of S422 inhibits tau cleavage at D421 in vitro [106].
e role of caspase cleavage of tau in neurodegeneration is
further complicated by a recent in vivo brain imaging study
in tau transgenic mice [113]. In this study, neurons with both
activated caspases and NFTs were generally not undergoing
apoptosis, suggesting that tau truncation by caspases may
correlate with tau �lament formation but not neurodegener-
ation. Caspase cleavage preceded NFT formation, consistent
with, although not proving, a cause-and-eﬀect relationship.
Interestingly, most NFT-containing neurons did not contain
active caspase.
Calpains, calcium-activated cysteine proteases, have also
been particularly implicated in tau cleavage. Calpain are
abnormally activated in the AD brain, and levels of endoge-
nous calpain inhibitor calpastatin are reduced [114, 115].e
formation of a 17 kDa fragment of tau is seen both in vivo and
in vitro [116, 117] and is triggered in neuronal cell culture by
treatment with aggregated A𝛽𝛽 [118]. e generation of this
17-kDa tau fragment has been attributed to calpain, as its
appearance is blocked by calpain inhibitor [118]. Although
the exact identity of the fragment is unknown, expression of
an approximate recombinant version, tau [45-230], can lead
to apoptosis in cell culture [118]. However, the presence of
the 17-kDa tau fragment has not been detected in human AD
brains, raising concerns about its relevance to pathogenesis.
Other proteases suggested to cleave tau but with less valida-
tion include thrombin, various cathepsins, and puromycin-
sensitive aminopeptidase [104]. e proteasome has also
been implicated and may be particularly important for the
degradation of misfolded tau [119, 120].
3.2. Frontotemporal Dementia (FTD)
3.2.1. Tau Mutations in FTD. In 1998 mutations in the
tau gene were discovered to be associated with frontotem-
poral dementia with parkinsonism linked to chromosome
17 (and speci�cally characterized by tau pathology, now
called FTDP-17T) [121–123]. Initially identi�ed mutations
cluster in and around the regions encoding the microtubule
binding domains, suggesting that perturbed ability to bind
microtubules might be involved in neuronal destruction and
death in these families. e FTDP-17T mutations provided
clear evidence that alterations in tau alone are suﬃcient to
cause neurodegenerative disease and strongly suggested that
aberrant tau plays a pathogenic role in other tauopathies,
including AD.
To date nearly 40 mutations associated with FTDP-17T
or related disorders have been identi�ed (reviewed in [124])
(Figure 4).ese are all either missensemutations, mutations
that aﬀect splicing, or both, and almost all cluster in the
portion encoding the C-terminal region or in an intervening
sequence near exon 10. e C-terminal missense mutations
all appear to impair tau binding to microtubules and the
ability of tau to promote microtubule assembly, while a
disease-associated mutation of a conserved arginine in the
N-terminal region has been found to disrupt binding to the
p150 subunit of the dynactin complex [125]. Most of the
silent mutations increase the 4R-to-3R ratio by modulating
alternative splicing of exon 10. Missense mutations found
within exon 10 only aﬀect the three 4R isoforms, while those
found outside this region aﬀect all six tau isoforms. Along
with the consistent tau deposition in these familial cases
and the observation that complete knockout of tau in mice
does not lead to neurodegeneration, the fact that all but
one of the disease-associated mutations [85] are dominant
strongly suggests a gain of a toxic function: one normal copy
remains, and in the case of exon 10 missense mutations, even
the 3R tau translated from the disease allele is normal. No
disease-associated mutations have been identi�ed that lead
to either a truncated protein or the nonsense-mediated decay
of message.
Diﬀerences in the clinical and pathological phenotypes
are seen between the various tau mutations (reviewed in [8,
124]).While manymutations lead to a phenotype resembling
FTDP-17T, others lead to phenotypes overlapping or identi-
cal to Pick’s disease, corticobasal degeneration, progressive
supranuclear palsy, or AD. Some mutations lead to tau
pathology in both neurons and glial cells, while others lead
to tau pathology primarily or strictly in neurons. How-
ever, rather than suggesting speci�c phenotypic diﬀerences
between tau mutations, many of these diﬀerences may re�ect
the diﬀerent genetic and environmental contexts in which
these mutations happen to reside. Ultrastructural diﬀerences
in tau �laments in brain tissue are also observed between
diﬀerent tau mutations, with some correlating with twisted
helical �laments, some with paired helical �laments (similar
to what is seen in AD) and still others with straight �laments
[124]. How thesemutationsmay lead to diﬀerently assembled
tau �laments is unclear.
3.2.2. Eﬀects of Mutations on Protein Aggregation. In general,
missense mutations apparently aﬀect tau’s role in micro-
tubule assembly. ese mutations are primarily found in
and around the microtubule binding domains and reduce
the ability of tau to promote microtubule assembly from
tubulin [126, 127]. Two exceptions are S305N and Q336R,
which enhance the ability of tau to facilitate microtubule




F 4: Mutations in tau associated with dominant familial frontotemporal dementia. (a) Almost all mutations in the coding region are
found in the �-terminal region, in and around the microtubule binding domains. Some of these are speci�c to the 4R isoforms, as they are
encoded in exon 10. Mutations in red lead to increased 4R tau relative to 3R tau. e asterisk near S352L denotes a single example of a lethal
recessive tau mutation, which presented as respiratory hypoventilation and displayed neuronal tau pathology [85]. (b) Other mutations are
found in the intron following exon 10, and these disrupt a hairpin structure in the pre-mRNA that regulates exon 10 inclusion/exclusion.
splicing [130]; thus, distinguishing the mechanism by which
this mutation exerts pathogenicity is diﬃcult. However, the
ability of the Q336R mutation to enhance the microtubule
binding role of tau again suggests that the balance of tau
proteins capable of interacting with microtubules may be
a critical factor ultimately dictating whether tau will self-
assemble into �laments or not. Other evidence suggests that
missense mutations may directly confer the ability of tau
to form �laments. Some studies, for instance, show that
a wide range of missense mutants (R5L, K257T, I260V,
G272V, ΔK280, P301L, P301S, G335V, Q336R, V337M, and
R406W) promote in vitro formation of �laments in the
presence of polymerization-inducing agents such as heparin
and arachidonic acid [129, 131–137]. Filament formation has
also been observed in neuroglioma cells upon expression of
mutant tau [138].
Phosphorylation is also thought to be critical to the
pathogenicity of tau (reviewed in [49]). Tau is phosphorylated
in multiple sites by multiple kinases, but some sites tend
to be more phosphorylated in tau pathology. Studying the
role of these phosphorylations in tauopathies is fraught with
diﬃculties however. In vitro phosphorylations by particular
kinases are typically challenging to con�rm in vivo, and
the order of events (phosphorylation vis-à-vis microtubule
dissociation or �lament formation) is still unclear. Some
kinase inhibitors have been shown to dramatically reduce
tau pathology in transgenic mice [139, 140], but such agents
notoriously lack speci�city. Nevertheless, some evidence has
been reported that disease-associated taumissensemutations
can lead to enhanced phosphorylation [141], and hyper-
phosphorylation can induce tau self-assembly into �laments
[142]. Other studies show that tau mutants bind less to
phosphatase 2A [143], the principal phosphatase in the
brain, which associates with the microtubule binding repeat
domains.
3.2.3. Eﬀects of Mutations on Splicing. Roughly half of the
identi�ed tau mutations associated with FT�P-17 aﬀect the
alternative splicing of exon 10 (reviewed in [8, 124]) (Figure
4). While a number of these are intronic mutations near the
exon 10 5′ splice site, others are mutations in the coding
region of exon 10. Virtually all of these mutations lead to an
increased inclusion of exon 10 and therefore an increase in
the 4R-to-3R ratio.
e silent and intronic mutations that increase in 4R tau
would be expected to have the opposite eﬀect onmicrotubule
binding to most of the missense mutations: the former would
lead to increased binding while the latter decrease binding.
How then can both types of mutations lead to �laments





















































in 4R tau saturates the binding sites on microtubules and
thereby results in unassociated 4R tau that is more prone to
phosphorylation and self-assembly [124]. Another possibility
is that higher association with microtubules may create
higher local concentrations of 4R tau and therefore a better
microenvironment for assembly.
e silent and intronic mutations near the exon 10 5′
splice site enhance exon 10 inclusion through two general
mechanisms: altering linear cis splicing elements or desta-
bilizing a stem loop structure at the exon-intron junction.
e stem loop structure was hypothesized [121, 122, 144]
upon the initial discovery of FTDP-17 mutations in the
tau gene, noting the apparent self-complementarity in this
region. Subsequent determination of the solution structure
of an oligonucleotide based on this exon-intron junction
by nuclear magnetic resonance spectroscopy [145] led to
re�nement of the stem loop model to seven speci�c base
pairs (Figure 4), with an adenosine bulge between the sixth
and seventh base pair. e structure further shows that
this unpaired purine ring is intercalated back into the A-
form RNA duplex. Disease-associated mutations would be
predicted to destabilize the stem loop andmake this sitemore
available to splicing factors (speci�cally the U1 snRNP that
interacts with 5′ splice sites; see Figure 4).
ermal stability studies of oligonucleotides demon-
strated that disease-associated mutations within the puta-
tive stem loop lower the melting temperature of the RNA
duplex (i.e., where the double-stranded RNA dissociates to
the single-stranded form) [145, 146]. A minigene construct
encoding exon 9–11 recapitulates normal tau exon 10 splicing
for the wild-type sequence and increased exon 10 inclu-
sion for disease-causing mutations [147]. is minigene has
been used to demonstrate that other mutations speci�cally
designed to enhance stability of the stem loop (and located
distal to theU1 snRNP binding site) reduce exon 10 inclusion
to decrease 4R/3R as predicted [146].
Other evidence has been taken to suggest that the stem
loop is not a biologically relevant structure and that these
intronic mutations instead either enhance the complemen-
tarity of the 5′ splice site with the U1 SNP or aﬀect an intron
splicing silencer (ISS) and the binding of a repressor protein
[130, 148, 149]. However, U1 SNP complementarity changes
cannot explain the eﬀects of all the mutations in this region,
an ISS cannot explain the eﬀects of stem-loop stabilizing
mutations, and no protein factor involved in ISS recognition
at this site has been identi�ed.
Other disease-causing mutations outside the stem loop
can also increase exon 10 splicing, likely due to strengthening
of an exon splicing enhancer (ESE) or weakening of an ISS
or an exon splicing silencer (ESS). Putative ESE regions have
been identi�ed in exon 10 [148, 150], with one being purine-
rich ESE and where mutations N279K and ΔK280 reside.
e splicing factor Tra2𝛽𝛽, part of a class of RNA-binding
proteins that contain serine- and arginine-rich (SR) domains,
binds to this purine-rich ESE to enhance exon 10 inclusion
[150]. In addition, an intron silencer modulator sequence
element has been identi�ed just downstream of the stem loop
[149].
3.2.4. Parkinson’s and Others. Tau pathology and tau muta-
tions are found in certain forms of parkinsonism, which
is a PD-like movement disorder without all the de�ning
pathological features of PD per se [151]. One example is
FTDP-17T, mentioned earlier. However, recent genomewide
association studies (��AS) have identi�ed the MAPT gene
as a risk factor for sporadic PD [152–155]. is is especially
surprising as PD typically does not display NFT pathology.
In contrast, MAPT has not been identi�ed as a genetic risk
factor for AD, although AD is de�ned by the presence of
tau pathology. Perhaps this is yet another piece of evidence
that NFTs are not the form of tau that is most pathogenic.
Interestingly, tau exon 10 splicing has been reported to be
altered in PD, with an increase in 4R isoforms [156], similar
to that observed with dominant FTD-associated MAPT
mutations.
Tau pathology is also observed in chronic traumatic
encephalopathy (CTE), in which multiple concussions or
other head injuries elicit neurodegeneration with dementia
and PD-like symptoms [157]. e disease is commonly
found in athletes involved in contact sports and in military
personnel exposed to blasts. One subtype of CTE is dementia
pugilistica, named for its associationwith professional boxers,
among whom Muhammad Ali is perhaps the most well-
known case. e role of NFTs in pathogenesis is unclear in
CTE, as it is in other tauopathies. However, the presence of
similar pathology to that seen with tau mutations that cause
other neurodegenerative diseases suggests that some form or
forms of aberrant tau are responsible.
3.2.5. Animal Models. A number of transgenic mice express-
ing tau have been developed in order to generate disease
models for tauopathies, and some show tau pathology and
neurodegeneration as well as behavioral de�cits (reviewed
in [9]). ese mice have provided critical in vivo models for
determining the role of aberrant tau in neurogeneration. For
instance, evidence suggests that microgliosis and synaptic
pathology may be the earliest manifestation of neurode-
generative tauopathies and that abrogation of tau-induce
microglial activation may be therapeutically bene�cial [96].
Crossing these mice with those that overproduce A𝛽𝛽 has
provided important models for AD that have shed light
on the role of tau with respect to A𝛽𝛽 [72]. A mouse line
transgenic for human genomicMAPT expresses all six brain
isoforms of tau and allows the study of the splicing of human
tau in vivo [158]. Another mouse model likewise provides
alternative splicing of the human transgene [159]. Moreover,
knockout of endogenous mouse tau alleviates A𝛽𝛽-induced
memory de�cits [47], suggesting that targeting tau may be a
worthwhile AD therapeutic strategy, although another report
suggests the opposite [70].
Questions remain regarding the pathological role of tau
�laments and neurodegeneration. �hile most transgenic
tau mice suggest that �lament formation is connected to
neurodegeneration (see [160]), results with a mouse line
containing an inducible tau gene showed that suppressing
tau improved memory even though neuro�brillary tangles
continued to grow [99]. One important caveat to this study:
tau levels under suppressed conditions in these mice were
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still dramatically higher than wild-type mice. Other evidence
in worms, �ies, and zebra�sh suggest that tau can cause
neurodegeneration in the absence of �lament formation [97,
98, 161]. Nevertheless, it would be surprising if tau �laments
within neuronal cell bodies and along axonal and dendritic
projections are compatible with normal neuronal function
and health.
4. Strategies for Targeting Tau
4.1. Tau Kinases. As hyperphosphorylated tau is associated
with NFTs and tau-related neurodegenerative diseases, inhi-
bition of the responsible kinases has been a top strategy for
targeting tau for the prevention or treatment of AD and other
tauopathies [162]. Inhibitors of GSK3𝛽𝛽 and CDK5 have been
of particular interest. Treatment with theGSK3 inhibitor LiCl
induces a reduction of tau phosphorylation at Ser-202 and
Ser-396/404 but not at Ser-262 or Ser-422 andhas been shown
to decrease tau aggregation and reduce axonal degeneration
in tau transgenic mice [139].
LiCl is not selective for GSK3𝛽𝛽 versus GSK3𝛼𝛼 and can
have many other oﬀ-target eﬀects, making assessment of its
ability to inhibit tau phosphorylation via GSK3𝛽𝛽 problem-
atic. However, an apparently selective GSK3 inhibitor AR-
A014418 was also found to reduce tau phosphorylation, �la-
mentous tau, and axonal degeneration aer oral administra-
tion for onemonth in tau transgenicmice [139]. An analog of
AR-A014418 entered into clinical trials forAD in 2007, but its
development has since been discontinued. Another selective
GSK3 inhibitor, Nypta (Tideglusib), is noncompetitive for
ATP [163] and appears to be well tolerated and to improve
cognitive performance in a 4–6-week clinical trial [164].
Although the study was not large enough to be statistically
signi�cant and target engagement was not clear, Tideglusib
has entered Phase IIb trials.
While such results seempromising inmanyways,GSK3 is
important for normal human physiology; as its name implies,
it is critical to proper glycogen metabolism. Moreover, a
selective GSK3 inhibitor was found to cause neurodegen-
eration in healthy wild-type mice [165], suggesting that at
least some level of GSK3 activity is essential to neuronal
function.erefore, although abnormally high GSK3 activity
is associated with several diﬀerent diseases (diabetes, cancer,
and bipolar disorder) and GSK3 appears to be a promising
target, complete inhibition is apparently not desirable.
Cdk5 has also been considered a potentially worthwhile
target, especially as this kinase is not involved in the cell
cycle and is active in postmitotic cells [166]. However,
the development of speci�c Cdk5 inhibitors has proven
challenging. Other cdks as well as GSK3 are typically aﬀected
as well. Dual Cdk5/GSK3 inhibitors may be desirable, but
other cdks should be avoided so as not to interfere with
cell replication. Relatively nonspeci�c kinase inhibitors have
also been considered, with the idea that multiple kinases
phosphorylate tau, and hitting many of these partially
would reduce tau phosphorylationwhileminimizing toxicity.
Indeed, one such compound, SRN-003-556, which inhibits
GSK3, cdk1, PKA, PKC, and ERK2 to similar degrees,
reduced tau phosphorylation and reduced motor de�cits in
a tau transgenic mouse model but without aﬀecting NFT
count [140], further evidence that NFTs per se may not be
pathogenic. Nevertheless, great care should be taken to de�ne
the range of targets of this compound and to pro�le its
toxicology.
4.2. Tau Aggregation. e assembly of tau into neurotoxic
oligomers or �brils makes blocking tau-tau interactions a
reasonable strategy for therapeutic intervention. A number
of screens in search of compounds that inhibit tau self-
assembly have been carried out, and a variety of compound
types have been identi�ed, including phenothiazines, por-
phyrins, polyphenols, cyanine dyes, aminothienopyrazines,
anthraquinones, phenothiazolyl hydrazides, and rhodanines
[167]. Many of these screens were carried out using the
binding of thio�avin T as a readout. io�avin T binds to
cross-𝛽𝛽-�bril structures ofmany assemble proteins, including
A𝛽𝛽 and tau, and such binding results in �uorescence. Com-
pounds identi�ed in such screensmay inhibit �bril formation
but not soluble oligomers and other assemblies. Indeed,
the potential to increase soluble oligomers exists. erefore,
counterscreens are needed to ensure that compounds block
early steps in the aggregation process. One example is to tag
tau with a �uorescent moiety and use �uorescence polariza-
tion as a readout, as increased size of the assemblies (e.g.,
monomer to dimer to trimer, etc.) results in an increased
signal [168].
emost advanced tau assembly inhibitor is the phenoth-
iazine dyemethylene blue (Rember). In 2008, this compound
was reported to slow cognitive decline in a small Phase
II clinical trial over almost one year, although this result
was complicated by the fact that the highest dose led to
lower than expected drug exposures, and no evidence for
target engagement was reported [169]. A study in a tau
transgenic mouse model, however, showed that very high
doses that lowered soluble tau levels also resulted in cognitive
improvement [170]. While a Phase III trial would help clarify
the eﬃcacy of methylene blue in humans, no such trial has
yet been initiated. However, a second-generation methylene
blue analog, LMTX, is allegedly in line for a Phase III trial.
No other tau aggregation inhibitors are in clinical trials at this
time.
Among the more promising new approaches to the
search for eﬀective tau assembly inhibitors is a structure-
based design strategy, targeting the cross-𝛽𝛽-sheet structure
of aggregated tau. While the detailed structure of tau �brils
is unknown, the structure of �brils of the tau peptide
VQIVYK, residues 306–311, was deduced by x-ray micro-
crystallography [171] and found to be a “steric zipper” of
𝛽𝛽-sheets. is short tau peptide is critical for tau assembly
in the context of the full-length protein and on its own
assemble into �brils similar to that formed by tau itself. D-
peptides were computationally designed to strongly interact
with this structure and prevent �bril elongation [172]. One
such peptide was found to delay �bril formation, even at
substoichiometric concentrations, and could also inhibit
�bril elongation. Small changes to the structure of this D-
peptide rendered it ineﬀective, and the active peptide was
Scienti�ca 11
found to have no eﬀect on A𝛽𝛽 �bril formation, a remarkable
demonstration of speci�city. �hile this D-peptide itself is
not a good drug candidate (peptides, even D-peptides, rarely
are), it may be a reasonable starting point for drug design and
validates the structure-based design approach.
Despite some promising advances in tau aggregation
inhibitors, a number of issues will need to be addressed to
facilitate translation into the clinic. First, the stoichiometry
required to eﬀectively engage tau and show eﬃcacy should be
understood for a given agent. In most cases, tau aggregation
inhibitors need to be at least equimolar with tau protein in
order to have the desired eﬀects. Secondly, the speci�city of
the compounds must be established to ensure that normal
protein-protein interactions are not unduly aﬀected. ird,
the steps in tau assembly that are aﬀected by the compound
should be elucidated. As mentioned earlier, �brils per semay
not be the primary neurotoxic entity, and blocking �bril
formation alone may lead to the buildup of more deleterious
soluble oligomeric assemblies. Fourth, the ability of the com-
pounds to interact with free tau versus microtubule-bound
tau should be determined or otherwise address whether
there is interference with normal tau functions. Although the
knockout of tau in mice leads to viable, fertile, and (for the
most part) healthy mice, the eﬀect of conditionally knocking
out tau is presently unknown.
4.3. Tau Clearance. Stimulating the natural ability of cells to
clear awaymisfolded or aggregated proteins has been another
strategy for targeting aberrant tau. One speci�c approach is
by enhancing degradation of tau by the ubiquitin-proteasome
system. Misfolded proteins are tagged with chains of ubiq-
uitin that enable interaction with and breakdown by the
proteasome. is process can apparently be stimulated with
inhibitors of the ATPase activity of heat shock protein
(HSP) 90, a molecular chaperone involved in protein refold-
ing. Inhibition of this HSP90 activity results in increased
expression of HSP70, which together with CHIP (the car-
boxyterminus of HSP70-interacting protein) is involved in
the ubiquitination of misfolded proteins [173]. Knockout
of CHIP in mice results in elevated phosphorylated tau,
suggesting that HSP70/CHIP is involved in the degradation
of this particular form of tau [174]. Consistent with this
notion, HSP90 inhibitors increase proteasomal degradation
of phosphorylated tau through HSP70/CHIP in cell culture
[175, 176] and decrease hyperphosphorylated tau in tau
transgenic mice [176, 177].
Toward the identi�cation of small-molecule stimulators
of the ubiquitin-proteasome system to enhance the clearance
of deleterious proteins, the discovery that a proteasome-
associated deubiquitinating enzyme, USP14, inhibits protea-
somal degradation of proteins by trimming oﬀ ubiquitin
chains inspired a high-throughput screen to �nd inhibitors of
USP14 activity [120]. e hit compound that emerged from
this screen, dubbed IU1, reversibly inhibited USP14 and did
so selectively over other deubiquitinating enzymes. IU1 could
also stimulate the degradation of tau in a concentration-
dependent manner in cell culture, and this tau degrada-
tion required USP14 and active proteasome complexes. e
degradation of another protein implicated in neurodegen-
eration, TDP-43, was likewise enhanced by IU1, while a
ubiquitin-independent substrate of the proteasome was not
aﬀected.
Monomeric,misfolded tau can be degraded by the protea-
some, but aggregated forms of tau cannot, as such aggregates
cannot pass through the proteasome pore. However, protein
aggregates as well as whole intracellular organelles can be
cleared through a process called autophagy (literally, self-
eating) [178]. In one type of autophagy (macroautophagy)
protein aggregates or organelles are enveloped into vesi-
cles that then fuse with lysosomes for degradation. Some
evidence suggests that reduction of this process can lead
to neurodegeneration [179, 180] and that enhancement of
autophagy can help clear out aggregated proteins associ-
ated with neurodegeneration [181].e immunosuppressant
drug rapamycin can enhance macroautophagy and prevent
plaques, NFTs, and cognitive de�cits in an AD mouse
model [182]. However, the safety of this agent for long-term
treatment of AD in humans is a serious concern. Recent
results suggest that trehalose also activates macroautophagy,
reduces insoluble tau, and is neuroprotective in a tau trans-
genic mouse model [183], although trehalose has multiple
biological eﬀects, and the safety of this agent at chronic
pharmacological doses is likewise unclear. Other means
of pharmacologically increasing autophagy that are more
speci�c may be required, but even then, the consequences of
chronic stimulation of autophagy are unclear.
4.4. Antibodies. Active and passive immunization targeting
tau is another promising approach for the prevention and
treatment of AD and other tauopathies [184]. e impetus
for this approach was promising �ndings on the use of anti-
A𝛽𝛽 antibodies in transgenic mouse models, demonstrating
that A𝛽𝛽 plaques could be prevented in youngermice and even
cleared in older mice and that cognitive de�ciencies in these
mice could be prevented or reversed, even upon peripheral
administration.ese results have led to a number of clinical
trials for the treatment of AD. Despite the preconceived
notion that antibodies cannot cross the blood-brain barrier,
studies show that low levels of anti-A𝛽𝛽 antibodies do access
the brain and elicit clearance of amyloid plaques. However,
these plaques are extracellular, while tau and tau pathology
is largely intraneuronal, suggesting that anti-tau antibodies
may not be capable of engaging their target. Nevertheless,
initial evidence shows that tau pathology can be reduced and
behavioural phenotypes slowed by active immunization with
antiphosphotau peptide in tau transgenic mice [185–188].
Passive immunization has likewise shownpromise [189, 190].
How might antibodies prevent tau pathology? One pos-
sibility is that they enter neurons through endocytosis,
although there is no evidence that this occurs, and even if
it did, the antibodies would have to somehow escape the
endocytic vesicles to gain access to tau in the cytoplasm.
Another possibility is that tau is secreted from neurons to
some degree and that this allows the spread of tau pathology
from neuron to neuron, a mechanism discussed earlier. In
this scenario, anti-tau antibodies would interact with tau at
synapses and intercept misfolded or aggregated tau before it
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is taken up by the neighboring neuron. Consistent with this
idea is the fact that tau is found in the CSF and is considered
a promising biomarker for AD [88].
4.5. Tau RNA. Because of the diﬃculty in targeting the
tau protein directly (it is not obviously “druggable,” as it
has no natural “ligands” per se) and the uncertainty of
targeting enzymes that modulate tau (e.g., kinases), some
have considered targeting the tau mRNA to either lower
overall tau protein levels or to shi splicing in a potentially
therapeutically productive way. e idea of knocking down
the tau message with siRNA or reducing tau protein transla-
tion via antisense oligonucleotides is based on the �ndings
in mice that knockout of the MAPT gene attenuates the
learning andmemory de�cits of FAD-mutant APP/presenilin
transgenic mice [47], which suggests that tau is critical to
the pathogenic process initiated by aggregated forms of A𝛽𝛽.
Although most reports on MAPT knockout suggest that
the mice are normal, fertile, and healthy, the possibility of
compensation (e.g., by MAP1) cannot be excluded. As no
conditional MAPT knockout mice have yet been reported,
it is unclear if tau is critical for normal neuronal function
in vivo, so complete ablation of tau by siRNA or antisense
oligonucleotides may not be desirable. Also, another report
describes crossing a tau knockout with a humanmutant APP
mouse leading to increased axonal degeneration [70].
Shiing the splicing of tau pre-mRNA is a more subtle
strategy that should not aﬀect overall levels of tau protein.e
rationale for this approach is the �nding that nearly half of
the ∼40mutations in theMAPT gene that are associated with
FTD alter the balance of tau exon 10 splicing to increase the
ratio or 4R to 3R tau isoforms. is skewing of tau splicing,
with no change in the encoded wild-type protein sequence, is
suﬃcient for tau pathology, neurodegeneration, and demen-
tia. erefore, use of agents that can shi the splicing back
toward a more normal 1 : 1 physiological ratio, (or even in
favor of 3R) may be bene�cial in treating these FTDs. Such
agents might also be therapeutic for AD as well, although
there is little evidence that the 4R-to-3R ratio is altered in AD.
Antisense oligonucleotides that target the exon10-intron10
boundary can shi splicing in this potentially bene�cial way.
ese include antisense directed to the linear sequence at
this boundary [191] as well as bipartite oligonucleotides
[192] directed to the 5′ and 3′ regions that �ank the hairpin
structure at this boundary, which prevent access by the U1
snRNP. e search for small, drug-like molecules that bind
and stabilize this hairpin has also identi�ed compounds such
as neomycin and mitoxantrone [193–197]. However, these
compounds lack speci�city for the tauRNAhairpin structure.
4.6. Other Strategies. Several other approaches to targeting
tau or compensating for potential loss of tau function
have been explored. One of these is to target the prolyli-
somerase PIN1, which switches speci�c tau p-Ser/r-Pro
motifs between trans- and cis-rotamer forms [198]. Recent
evidence using tau pT231-P232 rotamer-speci�c antibodies
[199] suggests that the cis-, but not the trans-, rotamer is an
early conformer associated with AD progression; that PIN1
restores the ability of cis-pT231-Tau to promote microtubule
assemble; that cis-pT231-Tau is more stable and more prone
to aggregation than trans-pT231-Tau; that cis-, but not trans-
, pT231-Tau correlates with NFTs in the AD hippocampus;
that PIN1 promotes cis-to-trans isomerization of pT231-
Tau in AD mouse models. us, increasing PIN1 activity
may be a worthwhile strategy for therapeutic intervention
for AD at the level of tau. How to do this, however, is not
obvious. Alternatively, immunotherapy with the conformer-
speci�c antibodies might block the pathogenic functions of
cis-pT231-Tau.
Reducing the acetylation of tau may be another reason-
able approach for lowering pathogenic forms of tau [200].
Acetylation at lysines oen competes with ubiquitination at
the same sites. us, acetylation can prevent the degrada-
tion of misfolded tau by the ubiquitin-proteasome system.
Tau is acetylated by the lysine acetyltransferase p300 and
deacetylated by the lysine deacetylase SIRT1 [201]. us,
inhibition of p300 activity or stimulation of SIRT1 activity
might facilitate ubiquitination and proteasomal degradation
of misfolded tau. Indeed, a small molecule inhibitor of
p300 has been shown to prevent neuronal accumulation of
phosphorylated tau [201]. However, p300 and SIRT1 have
many substrates, raising questions about the consequences of
altering their levels of activity.
Another approach is to pharmacologically rescue the
potential loss of function of tau in stabilizing microtubules.
While the knockout of tau does not result in neurodegen-
eration and none of the FTD-associated MAPT mutations
result in truncation or deletion of large regions of the protein,
it remains possible that misfolded or aggregated tau might
lead to insuﬃcient levels of tau protein for microtubule
stabilization. For this reason, antimitotic agents that act as
microtubule stabilizers have been explored for their ability to
rescue this tau function.One such agent, paclitaxel, prevented
axonal transport de�cits and motor impairments in a tau
transgenic mouse [202], and epothilone D improved micro-
tubule density, axonal integrity, and cognition of another
tau mouse model [203], even in aged mice that already had
pathology [204]. An epothilone analog has likewise shown
bene�t [205]. A peptide called NAP also stabilizes micro-
tubules and (surprisingly) reduces tau hyperphosphorylation
and ameliorates cognitive de�cits in tau mouse models [206–
208]. Intranasal delivery of NAP has shown some promise in
a phase II clinical trial.
5. Conclusions and Perspective
Substantial evidence supports the tau protein as a key
contributor to the pathogenesis of AD. However, the form
of tau that is neurotoxic, the means by which this toxicity
is transmitted, and the role of A𝛽𝛽 in triggering aberrant tau
are all unresolved issues. Misfolded and/or aggregated tau
protein appears to be responsible, but the exact nature of
the pathogenic form(s) (e.g., oligomeric state and degree of
phosphorylation) remains unclear. Despite this uncertainty,
genetic studies in mice suggest that reducing tau expression
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in the MAPT gene itself indicate a pathogenic role of aber-
rant tau. Moreover, as tau pathology correlates better with
neurodegeneration than amyloid plaques, pharmacological
intervention at the tau level may be eﬃcacious later in the
disease process than it would be at the A𝛽𝛽 level, which may
require presymptomatic diagnosis and treatment.
Many diﬀerent strategies have been pursued in the hopes
of intervening therapeutically at the level of tau (Figure
5). Nevertheless, tau remains relatively underdeveloped as a
therapeutic target, especially compared with A𝛽𝛽. is is due
to the unresolved issues mentioned previously along with the
fact that the tau protein itself is not a typical “druggable”
target, with endogenous small molecule ligands or otherwise
containing pockets to which drug molecules might obviously
bind in a pharmacologically meaningful way. Together, these
challenges make it diﬃcult to decide on a suitable strategy for
drug discovery. More basic research is needed to understand
the role of tau in neurodegenerative diseases to identify new
targets and approaches for pharmacological intervention. In
addition, the delivery of tau-targeting agents to the brain
is a major impediment; novel delivery approaches to the
brain, such as nanoparticles [209], should be explored in
conjunction with drug discovery.
In the meantime, however, one or more of the current
approaches may eventually bear fruit in the form of an
approved drug for AD and/or related disorders, so these
eﬀorts should continue. e medical need is simply too great
to halt the ongoing search for an eﬀective means of targeting
tau. Only one or a few of the many reasonable approaches
need to eﬀectively prevent or delay the onset or progression
of tauopathies, and at this point it is impossible to say which
of these approaches might be successful. us, all reasonable
strategies should be pursued in the hope of �nding disease-
modifying therapies for these devastating brain disorders.
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